FIELD: biotechnology.
SUBSTANCE: highly stable T-cell receptor is proposed that can be used in medicine. The resulting T-cell receptor having mutations in its hydrophobic core domain is used in a pharmaceutical composition for tumour treatment.
EFFECT: invention allows effective therapy of diseases associated with formation of tumours.
25 cl, 49 dwg, 13 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| T-CELL RECEPTORS | 2017 |
|
RU2775623C2 |
| IMPROVED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | 2021 |
|
RU2820497C1 |
| SPECIFIC BINDING MOLECULES | 2020 |
|
RU2825837C2 |
| HIGH-AFFINITY T-CELL RECEPTOR FOR AFP ANTIGEN RECOGNITION | 2019 |
|
RU2836365C2 |
| T-CELL RECEPTORS | 2018 |
|
RU2762255C2 |
| LABELED CHIMERIC EFFECTOR MOLECULES AND RECEPTORS THEREOF | 2014 |
|
RU2729463C2 |
| T-CELL RECEPTORS SPECIFIC RELATIVELY TO COMPLEX OF TUMOR ANTIGEN NY-ESO-1/HLA-A*02 | 2016 |
|
RU2775394C2 |
| METHODS OF PRODUCING CELLS EXPRESSING RECOMBINANT RECEPTOR AND RELATED COMPOSITIONS | 2019 |
|
RU2835579C2 |
| CHIMERIC ANTIBODY/T-CELL RECEPTOR STRUCTURES AND THEIR APPLICATIONS | 2016 |
|
RU2767209C2 |
| MODIFIED EXOTOXIN A PSEUDOMONADES | 2014 |
|
RU2687143C2 |
